Cutia Therapeutics, Ltd.
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cutia Therapeutics, Ltd.
Three Chinese Biotech IPOs Gross $639m In June
Genrix grossed $478.9m in the largest initial public offering from an innovative drug-focused biotech on Shanghai's STAR Market since February 2022. Meanwhile, Laekna and Cutia launched two smaller IPOs in Hong Kong.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Kedi Biomedicine (Hong Kong) Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice